Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

The FDA’s decision to approve mosunetuzumab marks the first bispecific antibody approved to treat follicular lymphoma.

An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.

An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.